Acute Sinusitis Market Research Report—Global Forecast till 2032

Acute Sinusitis Market Research Report Information By Treatment (Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers, Allergy Shots and Antibiotics), By End-Users (Hospitals & Clinics and Research Centers), By Diagnosis (Nasal Endoscopy, Imaging Test, Laboratory Test and Allergy Testing), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

ID: MRFR/HC/4371-CR | 126 Pages | Author: Rahul Gotadki | February 2022         

Acute Sinusitis Market Speak to Analyst Request a Free Sample

Global Acute Sinusitis Market Overview


Acute Sinusitis Market Size was valued at USD 2 Billion in 2022. The acute sinusitis market industry is projected to grow from USD 2.15 Billion in 2023 to USD 3.961 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.89% during the forecast period (2023 - 2032). Since acute sinusitis affects a large portion of the population worldwide, governments and businesses are collaborating to address the issue and offer better solutions, and government and business investments in technological advancements are raising the likelihood of a market expansion. Additionally, rising demand for over-the-counter medicines and treatments, such as nasal corticosteroids and nasal sprays, is a significant market driver that is projected to propel market expansion in the years to come.


Acute Sinusitis Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Acute Sinusitis Market Trends



  • Rising prevalence of acute sinusitis is driving the market growth


Since children's sinuses are smaller and less formed, adults are more likely to acquire acute sinusitis than children. Sinusitis has an incidence of 15–40 episodes per 1,000 patients annually, according to studies, and accounts for 0.5% of all upper respiratory tract infections. Additionally, general practitioners identify acute sinusitis as the second most typical infectious condition. Nearly 35 million Americans suffer from acute sinusitis, which is more common among elderly persons (45 to 64 years of age), according to a WebMD LLC. (US) article from February 2021. Acute sinusitis causes more than 15 million patients to visit doctors each year in the US. Furthermore, acute sinusitis has a yearly frequency of 6-15% around the world, according to the World Allergy Organisation. Therefore, it is anticipated that throughout the projected period, the rising incidence of acute sinusitis cases will propel the expansion of the  acute sinusitis market CAGR.


It is projected that a rising  trend in healthcare research and development expenditures will support market growth in the future. One of the main trends in the acute sinusitis industry is the emergence of biologics. Right now, omalizumab is the best solution. This drug has been approved for the treatment of severe allergic asthma in both the US and Europe. Omalizumab is being tested by researchers for its safety and effectiveness in treating chronic rhinosinusitis with nasal polyps. The  acute sinusitis market is predicted to grow as a result of the successful introduction of biologics like omalizumab. Key firms across the globe are continuously increasing their spending on marketing and innovation as a result of a continued focus on cost management and increased process efficiency. Thus, driving the acute sinusitis market revenue.


Acute Sinusitis Market Segment Insights


Acute Sinusitis Treatment Insights


The  acute sinusitis market segmentation, based on treatment includes Saline Nasal Spray, Nasal Corticosteroids, Decongestants, OTC Pain Relievers, Allergy Shots and Antibiotics. The antibiotics segment dominated the market. In order to prevent more severe complications from bacterial acute sinusitis affecting the frontal, sphenoid, or ethmoid sinuses, antibiotics are advised. For a very long time, antibiotics like macrolides, cephalosporins, and penicillins have been advised.


Acute Sinusitis End-Users Insights


The  acute sinusitis market segmentation, based on end-users, includes Hospitals & Clinics and Research Centers. The hospitals & clinics category generated the most income following a large number of patients seeking sinus treatment at the hospitals & clinics. The category is predicted to grow as a result of the rising incidence of acute sinusitis and the favorable reimbursement requirements. The ability to perform sophisticated sinus surgeries, the presence of technologically advanced medical equipment, and the infrastructure will all encourage segment expansion.


Figure 1  Acute Sinusitis Market, by End-Users, 2022 & 2032 (USD Billion)



Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Acute Sinusitis Diagnosis Insights


The  acute sinusitis market segmentation, based on diagnosis, includes Nasal Endoscopy, Imaging Test, Laboratory Test and Allergy Testing. The nasal endoscopy category generated the most income. A nasal endoscope, a specialized tool used during rhinoscopy, is used to view the sinus apertures and nasal passageways. The nasal mucosa, any abnormal growths or polyps, and any indications of inflammation or illness can all be seen clearly. The diagnosis and evaluation of the severity of acute sinusitis are aided by nasal endoscopy.


Acute Sinusitis Regional Insights


By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American acute sinusitis market area will dominate this market. North America's growth is boosted by its technological advancements in diagnostic services, rising spending, and simple accessibility to healthcare facilities. The prevalence of chronic diseases in the US is rising, which is accelerating market expansion there. The CDC estimates that 11% of Americans have acute sinusitis. An alarming pace of growth is being observed in the occurrence of acute sinusitis. The government and the manufacturers are collaborating to give better treatment options and are heavily investing in technical breakthroughs to address this issue. In the years to come, market expansion is also predicted to be fueled by rising consumer demand for over-the-counter drugs such decongestants, nasal sprays, and nasal corticosteroids.


Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 2  ACUTE SINUSITIS MARKET SHARE BY REGION 2022 (USD Billion)



Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe acute sinusitis market accounts for the second-largest market share. The market is growing as a result of a well-established healthcare infrastructure and system, rising allergic rhinitis rates, and widespread product accessibility. The demand for its treatment is expected to rise due to the rising frequency of chronic sinusitis and the notable geographic variations in sinus-related disorders in European nations. Similarly, it is projected that the market will be similarly impacted by the rising prevalence of allergic rhinitis. Approximately 20% of the population of Germany has at least one allergy, and only 10% of them choose to treat it properly, according to a study that was published in the World Allergy Organisation Journal. Further, the German acute sinusitis market held the largest market share, and the UK acute sinusitis market was the fastest growing market in the European region


The Asia-Pacific Acute sinusitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous acute and chronic diseases are becoming more commonplace at an alarming rate. India is home to 18% of the world's population with chronic respiratory disorders, according to the Institute for Health Metrics and Evaluation. Additionally, the market is expanding due to the growing demand for high-quality, affordable care. Aside from this, the region's simple access to treatment options and the rising number of people with sinusitis are fueling market expansion. Moreover, China’s acute sinusitis market held the largest market share, and the Indian acute sinusitis market was the fastest growing market in the Asia-Pacific region.


Acute Sinusitis Key Market Players & Competitive Insights


Leading market players are investing heavily in research and development in order to expand their product lines, which will help the acute sinusitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, acute sinusitis industry must offer cost-effective items.


Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  acute sinusitis industry to benefit clients and increase the market sector. In recent years, the acute sinusitis industry has offered some of the most significant advantages to market. Major players in the acute sinusitis market attempting to increase market demand by investing in research and development operations include Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others.


Sanofi is a healthcare organisation that is involved in the development, production, marketing, and discovery of numerous drugs and vaccines. Its product line also includes human vaccinations for defence against a number of bacterial and viral infections, medications for the treatment of cancer, uncommon disorders, and multiple sclerosis, and other goods. Additionally, the company sells consumer healthcare items for women's health, digestion, allergy, cough, cold, flu, and sinuses, pain, and vitamins, minerals, and supplements. Sanofi's research and development efforts are concentrated on developing a combination therapy to boost treatment efficacy and on developing innovative biologic formulations to create precision medicines.


The healthcare corporation Novartis AG specializes in the development, production, and marketing of pharmaceutical goods for prescription and over-the-counter use as well as products for eye care. It offers medications for the treatment of ailments such infections, hematologic diseases, solid tumors, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, and others. Through Sandoz, the business sells biosimilars and generic medications. In August 2020, intranasal corticosteroids and Xolair have been approved by Novartis AG for the treatment of rhinosinusitis with nasal polyps.


Key Companies in the acute sinusitis market include



  • Sanofi (France)

  • Abbott (US)

  • Bayer AG (Germany)

  • Aurobindo Pharma (India)

  • Bristol Myers Squibb (US)

  • Merck KGaA (Germany)

  • AstraZeneca (UK)

  • Reddy’s Laboratories Ltd (India)

  • Novartis AG (Switzerland)

  • GlaxoSmithKline plc (UK)


Acute Sinusitis Industry Developments


February 2022 Olympus, a leader in developing and distributing ground-breaking solutions for medical and surgical procedures, declared that their CELERISTM single-use sinus debride system has been approved by the FDA and will soon be offered for purchase. In general ENT and sinus/rhinology procedures, the CELERIS system is made to cut, coagulate, debride, and remove thin bone and soft tissue.


August 2021 When intranasal corticosteroids (INC) alone are not sufficient to address severe chronic rhinosinusitis with nasal polyps in patients 18 years of age and older, the European Commission (EC) has approved the use of Xolair (omalizumab) as an adjunctive therapy.


July 2021 The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as a treatment for people with chronic rhinosinusitis and nasal polyps, according to GlaxoSmithKline (GSK). This is a new indication for the interleukin-5 (IL-5)-targeting monoclonal antibody mepolizumab.


Acute Sinusitis Market Segmentation


Acute Sinusitis Treatment Outlook (USD Billion, 2018-2032)



  • Saline Nasal Spray

  • Nasal Corticosteroids

  • Decongestants

  • OTC Pain Relievers

  • Allergy Shots

  • Antibiotics


Acute Sinusitis End Users Outlook (USD Billion, 2018-2032)



  • Hospitals & Clinics

  • Research Centers


Acute Sinusitis Diagnosis Outlook (USD Billion, 2018-2032)



Acute Sinusitis Regional Outlook (USD Billion, 2018-2032)



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Scope:

Acute Sinusitis Report Scope
Report Attribute/Metric Details
Market Size 2022 USD 2 Billion
Market Size 2023 USD 2.15 Billion
Market Size 2032 USD 3.961 Billion
Compound Annual Growth Rate (CAGR) 7.89% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Diagnosis, End Users, Treatment and Region
Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others
Key Market Opportunities Rising  R&D initiatives and healthcare expenditure
Key Market Dynamics Increasing number of patients suffering from acute sinusitis Availability of several treatment and diagnostic options




Frequently Asked Questions (FAQ) :

The  acute sinusitis market size was valued at USD 2 Billion in 2022.

The  market is projected to grow at a CAGR of 7.89% during the forecast period, 2023-2032.

North America had the largest share in the  market

The key players in the market are Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), GlaxoSmithKline plc (UK) and Others.

The nasal endoscopy category dominated the market in 2022.

The antibiotics category had the largest share in the market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid